



# Robotic approach for rectal cancer, is the best approach?

Turgut Bora Cengiz, Emre Gorgun

Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, Cleveland, OH, USA

**Contributions:** (I) Conception and design: All authors; (II) Administrative support: All authors; (III) Provision of study materials or patients: All authors; (IV) Collection and assembly of data: All authors; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

**Correspondence to:** Emre Gorgun, MD, FACS, FASCRS. Department of Colorectal Surgery, Digestive Disease and Surgery Institute, Cleveland Clinic, 9500 Euclid Ave. A30, Cleveland, OH, 44195, USA. Email: gorgune@ccf.org.

**Abstract:** Rectal cancer surgery (RCS) practice has shown substantial changes after the introduction of minimally invasive techniques which provided shorter length of hospital stay and reduced morbidity rates compared to open surgery. Challenges about minimally invasive approach in rectal surgery settings are magnified when the rigid nature of the laparoscopic instruments intervene with the precise dissection, especially in the confined spaces such as pelvis. Robotic surgery, is a novel technique addressing the restrictions of the laparoscopic surgery by utilizing endo-wristed equipment, three-dimensional visualization, stable retraction and better ergonomics for the surgeon. Up-to-date, robotic surgery has reached 849,000 operations worldwide within multiple disciplines, including urology, gynecology and cardiothoracic surgery. Coherently, rectal surgery has been benefiting the ample opportunities that robotic system offers, yet, unavailability of the platform in every medical center, prolonged operative time and the increased economic burden of the surgery pose obstacles for the employment of the robotics globally. Debates keep climbing toward whether the purported advantages of the robotic system will actually translate into clinical effectiveness over conventional laparoscopy. This review article discusses the current role of robotic approach in RCS and future directions of the robotic RCS.

**Keywords:** Adenocarcinoma; rectal cancer; robotic; robotic surgery; rectum

Received: 05 February 2018; Accepted: 05 March 2018; Published: 30 March 2018.

doi: 10.21037/ales.2018.03.12

**View this article at:** <http://dx.doi.org/10.21037/ales.2018.03.12>

## Introduction

Minimally invasive surgery (MIS) is considered one of the leading advances in rectal cancer surgery (RCS) and has been exponentially utilized as a surrogate for open RCS (ORCS). Nevertheless, two recent randomized studies, ALaCaRT and ACOSOG Z6051 (1,2), have failed to show non-inferiority of the laparoscopic RCS (LRCS) against ORCS in terms of conversion and circumferential radial margin (CRM) positivity rates and raised concerns regarding the implementation of the laparoscopy in RCS settings.

Total mesorectal excision (TME), a technique first described by Heald *et al.* in 1982 (3), is currently the mainstay of oncologic resection in RCS. Achieving a

complete resection of the mesorectum requires meticulous dissection of the embryologic planes within the pelvis, where the rectum is in close proximity to vasculature and nerves. The incorporation of robotic systems into RCS have been anticipated to overcome the limited dexterity associated with laparoscopic surgery by introducing endo-wristed equipment that offers better articulation, tremor-free retraction and a stable, surgeon-driven camera platform. However, robotic surgery generally takes longer to perform than a laparoscopic approach and is more expensive. Both of these factors raise concerns about whether this novel technique offers surgeons and patients any advantages over laparoscopy in RCS. In this review, we will discuss the use of robotic systems in light of the most recent advances in



**Figure 1** Patient positioning in robotic rectal cancer surgery.

RCS as well as the results of an eagerly anticipated study called the *RO*botic versus *LA*paroscopic Resection for Rectal Cancer (4) trial, in which the authors compared da Vinci robotic system (Intuitive Surgical Systems, Sunnyvale, CA, USA) to conventional laparoscopic surgery.

## Methods

We performed a comprehensive search on PubMed using the key words “total mesorectal excision,” “robotic proctectomy,” “robotic surgery,” “laparoscopic surgery,” and “robotic rectal cancer.” All meta-analyses, randomized trials, prospective and retrospective cohorts, and reviews published between 2000 and 2017 in the English language were considered. We have also included unpublished data from our center where specified.

### *Patient selection and preoperative workup*

Patient selection for robotic RCS (RRCS) is one of the most important steps to optimizing surgical outcomes. A number of factors may restrict access to the pelvic cavity, including previous abdominal operations, male gender, low-lying tumors and obesity (BMI >30), although these are not absolute contraindications. Moreover, obese patients may benefit from undergoing RRCS versus LRCS as the former was associated with a quicker return of bowel function (median 3 *vs.* 4 days) and a shorter hospital stay (median 6 *vs.* 7 days) in one study (5).

Patient history and physical examination are essential parts of the preoperative workup as well as a full colonoscopy to rule out the presence of any potential synchronous lesions. Preoperative oral antibiotics and

mechanical bowel preparation are recommended to decrease the risk of surgical site infection. Thirty to 60 minutes prior to incision, intravenous antibiotics should be given to the patient as indicated in the Surgical Care Improvement Project (6) to help maintain optimal levels during surgery. Preoperative heparin prophylaxis and compressive devices decrease the risk of deep venous thrombosis.


### *Robotic procedure*

Prior to incision, the rectum is irrigated with saline, and a Foley catheter and orogastric tube are inserted. The patient is placed in a modified lithotomy position to ease access to the anus during intraoperative colonoscopy and to facilitate circular stapler placement. It also allows the surgical team to easily manipulate the upper abdomen between the patient's legs. Yellow sponge fins or padded stirrups are used to prevent peroneal nerve injury. A gel pad is placed on the operating table to provide decubitus support. Tape is placed around the patient's chest to help stabilize him or her and reduce pressure on the lower limbs when the operating table is tilted. Finally, both arms are tucked at the patient's sides (*Figure 1*).


Intraoperative sigmoidoscopy is routinely performed to locate the tumor and to evaluate the integrity of the anastomosis. Two monitors are placed on each side of the operating table to assist the surgical team.

Port placement is crucial because the surgeon must have enough space in which to manipulate the robotic arms, which can otherwise collide with one another. Port placement (*Figure 2*) is generally guided by the surgeon's experience. In our practice, five to six ports are commonly used, including one camera port and one assistant port.

When using S or Si generation, a 12-mm camera port is placed in the supraumbilical area with an open technique. An 8-mm port is placed in the left lower quadrant lateral to the umbilicus 10 cm apart; two additional 8-mm ports are placed—one in the right upper and one in the right lower quadrant. One assistant port is inserted on the right lateral to the robotic ports in equal distance from the right upper and lower quadrant trocars. A right upper quadrant robotic port (port 3) is used for splenic flexure mobilization and left colectomy. An additional robotic port (port 3P) is placed in the left-mid abdomen, lateral to the edge of the rectus muscle. This port, 3P, is used for pelvic dissection (anterior resection, low anterior resection, abdominoperineal resection procedures). The assistant port is used for bowel



**Figure 2** Port placement in robotic rectal cancer surgery.



**Figure 3** Robotic docking in rectal cancer surgery.

retraction, suction and irrigation purposes (*Figure 3*).

The operation begins by establishing pneumoperitoneum followed by the laparoscopic exploration of the tumor site and the rest of the abdomen. Once additional ports are entered, the patient is positioned in a right tilt along with a slight Trendelenburg so that the small bowel loops and the cecum can be removed from the pelvis. A medial-to-lateral dissection along with embryologic planes between the mesocolon and the retroperitoneum is made with monopolar cautery and scissors. The inferior mesenteric artery is identified, skeletonized and subsequently ligated with Hem-o-Lock clips (Weck Surgical Instruments, Teleflex Medical, Durham, NC, USA) 1 to 1.5 cm away from the aorta. The inferior mesenteric vein is also

identified at the inferior border of the pancreas, isolated and clipped. Further dissection is carried out between the mesocolon and Gerota’s fascia along the Toldt line.

After the gastrocolic and splenicocolic ligaments are divided, the lesser sac is entered and the left colon is mobilized. Once a medial-to-lateral dissection is performed and the splenic flexure is mobilized, the right upper quadrant robotic arm is switched from the right side to the left side. Pelvic dissection is then started. A mesorectal excision is made within an avascular plane between the mesorectal envelope and endopelvic parietal fascia, starting at the level of the sacral promontory. Dissection is continued toward the levator muscles, protecting the hypogastric plexuses while preserving the entirety of the



**Figure 4** Exteriorization of the specimen from ileostomy site.

mesorectum. Preferentially, the rectum is divided with a reticulating robotic stapling device.

At this particular point, a rare technique may be utilized in which the rectum can be transected under direct vision with a cautery hook. A purse string suture is then placed around the rectal cuff and subsequently anastomosis is established with a circular stapler. The specimen is exteriorized from the right lower quadrant incision with a wound protector, where an ileostomy will potentially be placed (*Figure 4*). Natural orifice specimen extraction through the anus has also been described in patients undergoing RCS.

A hybrid technique, also called a laparoscopic-assisted robotic technique, eliminates the need to reposition the robotic arms, thereby reducing the overall operative time. The robotic system is designed to work better in confined places such as the pelvis. Thus, the transition to robotic pelvic dissection for TME after laparoscopic mobilization of the splenic flexure facilitates dissection and prevents any disruption at the flow of the operation.

### **TME: transition to robotic era**

In the past ten years, some studies assessing LRCS have been published, allowing surgeons to gain a better and more concrete understanding of clinical and oncological outcomes. Initially, the MRC CLASICC trial (7) reported a 34% conversion rate and increased radial margin involvement compared to ORCS. However, during the study's 3-year follow-up period, there was no increase in local recurrences or any changes in disease-free survival and overall survival (8).

LRCS gained more popularity with the COREAN (9) and COLOR II (10) randomized controlled trials, which

reported surgically acceptable outcomes and no differences in oncologic quality of the specimen between ORCS and LRCS. In fact, LRCS was associated with better short-term postoperative findings. Moreover, three year follow-up in the COLOR II trial indicated that locoregional recurrence (5% *vs.* 5%), disease-free survival (74.8% *vs.* 70.8%) and overall survival rates (86.7% *vs.* 83.6%) were comparable between laparoscopic and ORCS (11), respectively.

On the other hand, the ALaCaRT (1) and ACOSOG Z6051 (2) trials further changed the approach to LRCS and failed to show noninferiority of laparoscopy against ORCS. The results of these two trials increased the skepticism about whether laparoscopy is preferential to ORCS in terms of mesorectal completeness and clear CRMs.

While discussions about laparoscopic TME continue, RRCS has emerged as a novel technique in RCS. Numerous trials, case-control studies and meta-analyses have compared RRCS with LRCS. Early reports depicted favorable or comparable results for RRCS (12-17). Although robotic surgery was associated with a longer operative time and higher costs, tumor-free CRM rates were lower and there was fewer postoperative complications and conversions. In their propensity score match analysis, Kang *et al.* (18) reported that patients who underwent RRCS were able to resume their bowel habits earlier, had a shorter length of stay and lower visual analog scale pain scores in the postoperative period.

A number of meta-analyses have been published in recent years, allowing us to evaluate this novel approach in RCS in more depth. Among these, Memon *et al.* (19) compared eight studies and concluded that RRCS was associated with fewer conversions to open, which is congruent with other studies. Similarly, Cui *et al.* (20) reviewed nine papers and found that RRCS was superior to LRCS in terms of conversions, intraoperative blood loss, hospital stay and short-term complications although operative time was longer.

The surgical community has eagerly awaited the results of *RObotic versus LAparoscopic Resection for Rectal Cancer* (4) trial, which concluded that RRCS did not differ from LRCS with respect to conversions, CRM positivity, number of harvested lymph nodes, quality of life and postoperative complications. Even though implementation of a non-standardized operating technique and surgeons with different levels of experience in robotic surgery may affect the outcomes, in the subgroup analysis, robotic surgery was found to be beneficial in male patients.

These recent meta-analyses seem to suggest that

**Table 1** Clinical outcomes of the robotic surgery

Author	Year	Number of patients	Type of surgery	Operative time, min	EBL, mL	LOS, days	Overall complication rate (%)	Conversion rate (%)
Kim <i>et al.</i> (21)	2010	100	RRCS	385±102	NA	11.7±6.7	20	2
		100	LRCS	297±83	NA	14.4±10	27	3
Baek <i>et al.</i> (22)	2011	41	RRCS	296 [150–520]	200	6.5	22	7.3
		41	LRCS	315 [174–584]	300	6.6	26.8	22
D'Annibale <i>et al.</i> (23)	2013	50	RRCS	270 [240–315]	NA	8 [7–11]	10	0
		50	LRCS	280 [240–350]	NA	10 [8–14]	22	12
Kang <i>et al.</i> (18)	2013	165	RRCS	309±115	133	10.8±5.5	20.6	0.6
		165	LRCS	277±81	140	13.5±9.2	27.6	1.8
		165	ORCS	252±88	275	16±8.6	24.8	NA
Yoo <i>et al.</i> (24)	2015	44	RRCS	316±65	239	11.4±5	38.6	0
		26	LRCS	286±51	215	11±6	26.9	0
ROLARR (4)	2017	237	RRCS	295±88	NA	8±5.8	33.1	8.1
		234	LRCS	261±83	NA	8.2±6	31.7	12.2

EBL, estimated blood loss; LOS, length of stay; RRCS, robotic rectal cancer surgery; LRCS, laparoscopic rectal cancer surgery; ORCS, open rectal cancer surgery; NA, not available.

RRCS provides at least similar to relatively better short-term surgical outcomes and may offer new aspects in RCS. Details of the clinical and oncologic outcomes of the selected reports are summarized in *Tables 1* and *2*, respectively.

### **Correlation of experience and cost**

Increased operating time and cost are the main drawbacks for RRCS. A recent study from our institution indicated that RRCS costs on average 30% more than ORCS and LRCS, which included the surgeon's learning curve and multiple procedures but not any additional costs associated with readmissions and reoperations during the study period (25). Similarly, in the ROLARR trial, robotic surgery cost \$1,131 more per operation than laparoscopy (4). Robotic surgery is more expensive due to fixed costs such as those for the operating theater and disposable robotic arms. Interestingly, Morelli *et al.* (26) reported that when the fixed costs were excluded, the overall costs of RRCS and LRCS were similar, especially as surgeons experience increased. Unpublished data from our institution suggests that it is possible to minimize the cost difference between open and robotic restorative proctectomies over the long

term by using a cost-conscious approach (using cautery and clips instead of vessel sealing device etc.) and increasing surgeon experience, both of which cut costs associated with operative theater, ileostomy closures and surgery-related readmissions and reoperations (*Table 3*). Of course, short-term data on robotic surgery show increased costs, as one would expect. Nevertheless, if more long-term comparisons show comparable economic outcomes, the value of RRCS may become clearer.

### **Learning curve**

In order to master a new technical skill, it is vital to practice it through continuous repetition. Jiménez-Rodríguez *et al.* (27) and Sng *et al.* (28) proposed similar 3-layered learning curves for robotic-assisted surgery for rectal cancer, which are: attaining skills, strengthening technique and gaining expertise. As surgeons' robotic skills improve, so does their ability to manipulate the console and utilize instruments, which subsequently leads to better surgical outcomes. Mastering robotic surgery skills may lead to less consumption of surgical equipment and lower surgery costs.

Operating time is frequently used as a primary predictor in learning curve studies to assess skill acquisition. On

**Table 2** Oncological outcomes of the robotic surgery

Author	Type of surgery	CRM positivity (%)	DRM, cm	Harvested lymph node number	DFS (%)	OS (%)
Kim <i>et al.</i> (21)	RRCS	3	2.7±1.9	14.7±9.7	NA	NA
	LRCS	2	2.6±1.8	16.6±9.1	NA	NA
Baek <i>et al.</i> (22)	RRCS	4.9	3.6	13.1	NA	NA
	LRCS	2.4	3.8	16.2	NA	NA
D'Annibale <i>et al.</i> (23)	RRCS	0	3	16.5	NA	NA
	LRCS	12	3	13.8	NA	NA
Kang <i>et al.</i> (18)	RRCS	4.2	1.9±1.4	15±9.4	83.5	NA
	LRCS	6.7	2±1.4	15.6±9.1	81.9	NA
	ORCS	10.3	2.2±1.7	17.4±10.9	79.7	NA
Yoo <i>et al.</i> (24)	RRCS	9.1	1.3±0.9	13.9±9	76.7	95.2
	LRCS	19.2	1.67±3	21.4±15.7	75	88.5
ROLARR (4)	RRCS	5.1	NA	23.2	NA	NA
	LRCS	6.3	NA	24.1	NA	NA

CRM, circumferential resection margin; DRM, distal resection margin; DFS, disease free survival; OS, overall survival; NA, not available; RRCS, robotic rectal cancer surgery; LRCS, laparoscopic rectal cancer surgery; ORCS, open rectal cancer surgery.

**Table 3** Overall cost comparison of open *vs.* robotic proctectomy

Years	Total (N=100)	Open proctectomy (N=68)		Robotic proctectomy (N=32)		P value
		n	Cost	n	Cost	
2011–2012	27	22	1±0.4	5	1.5±0.5	0.02
2013	38	26	1±0.8	12	0.96±0.3	0.14
2014	35	20	1±0.6	15	1.2±0.6	0.10
2017*	100	68	1±0.5	32	1±0.4	0.96

Asterisk indicates cumulative costs after 33 months including loop ileostomy closures, readmission and reoperations. Actual cost values are not presented due to our institution's cost privacy policy. Presented cost value was the ratio between the actual mean direct costs with standard deviation divided by actual mean direct cost of the open surgery.

average, 9 to 35 operations are necessary in order for surgeons to achieve the first phase of the learning curve (27–29) in RRCS whereas the learning curve of the LRCS varies 40 to 50 cases regarding operative time (30–32). Park *et al.* further compared the learning curves of the RRCS and LRCS, which showed no difference (33). Nevertheless, gaining competence in handling a host of possible intraoperative complications is also important to consider when interpreting learning curves. Thus, relying on operative time as a measure of learning is still controversial.

### **Robotic rectal surgery in challenging cases**

MIS is a more technically challenging procedure in obese patients where the maneuverability of the rigid laparoscopic instruments is highly restricted due to excessive fat tissue in the intra-abdominal area. Robotic surgery has the proposed benefit of increasing articulation in these patients. Our institutional data comparing RRCS and LRCS in obese patients who are case-matched regarding age, gender, body mass index (34.9 *vs.* 35.2 kg/m<sup>2</sup>, respectively), comorbidities, surgical and tumor characteristics showed that those who

**Table 4** Institutional data comparing robotic and laparoscopic proctectomies in obese patients

Variable	RP group (n=29)	LP group (n=27)	P value
<b>Intraoperative outcomes</b>			
Operative blood loss (mL), mean (SD)	434.0 (612.4)	339.4 (271.9)	0.68
Intraoperative transfusion, n (%)	6 (20.7)	5 (18.5)	0.84
Intraoperative complication, n (%)	2 (6.9)	0 (0.0)	0.49
Ureter injury	0	0	
Conversion to open surgery, n (%)	1 (3.4)	5 (18.5)	0.09
Operative time (min), mean (SD)	329.0 (102.2)	294.6 (81.1)	0.13
<b>Oncologic outcomes</b>			
Proximal margin (cm), mean (SD)	17.4 (6.2)	21.6 (9.3)	0.09
Distal margin (cm), mean (SD)	3.9 (2.1)	3.2 (2.0)	0.17
LN total, mean (SD)	25.5 (14.0)	21.8 (9.6)	0.52
Radial margin involved ( $\leq 1$ mm), n (%)	2 (6.9)	2 (7.4)	0.99
<b>Postoperative outcomes</b>			
Bowel movement (days), mean (SD)	3.2 (1.9)	4.3 (2.3)	0.01
Oral regimen (days), mean (SD)	3.7 (2.4)	4.6 (3.4)	0.59
Hospital stay (days), mean (SD)	6.4 (4.2)	8.4 (4.4)	0.02
Anastomotic leak, n (%)	0	0	
Overall SSI, n (%)	4 (13.8)	4 (14.8)	0.99
Wound disruption, n (%)	2 (6.9)	2 (7.4)	0.99
Sepsis, n (%)	1 (3.4)	1 (3.7)	0.99
Ileus, n (%)	4 (13.8)	8 (29.6)	0.15
Urinary tract infection, n (%)	1 (3.4)	1 (3.7)	0.99
Urinary retention, n (%)	7 (24.1)	5 (18.5)	0.61
Atelectasis, n (%)	2 (6.9)	0 (0.0)	0.49
Re-operation, n (%)	2 (6.9)	2 (7.4)	0.99
Re-admission, n (%)	4 (13.8)	6 (22.2)	0.41
Mortality, n (%)	0	0	

RP, robotic proctectomy; LP, laparoscopic proctectomy; LN, lymph node; SSI, surgical site infection.

underwent RRCS experienced earlier return of bowel function (3 vs. 4 days, median, respectively) and a shorter hospital stay (6 vs. 7 days, respectively) (5) (Table 4).

Abdominoperineal resection (APR) is still the preferred method for low-lying cancers that invade the sphincter muscles, but it requires high maneuverability within the pelvis. Moghadamyeghaneh *et al.* compared open, laparoscopic and robotic APR and found that MIS was

associated with better overall morbidity rates than open; the robotic technique was also associated with lower conversion rates than laparoscopy (34). Our unpublished institutional data suggest that patients robotic APR may be used safely and has comparable perioperative and financial outcomes with LRCS.

The endo-wristed nature of the robotic platform poses a great advantage over laparoscopy because it not

only provides better maneuverability during dissection of the tissues surrounding the rectum but also facilitates transection of the rectum via the robotic stapler device, which provided better articulation skills. A widened range of motion and 90° of articulation led to a better angle of transection, fewer stapler firings and decreased cost (35). Yet, the literature lacks data regarding the robotic stapler.

### Future directions in robotic surgery

Single-incision laparoscopic surgery (SILS) has been introduced to decrease port-related complications, but technical challenges disrupted the development of SILS, especially in more complex operations where delicate tissue manipulation is needed. Robotic surgery has the ability to overcome such restrictions by increasing articulation, which in turn decreases the risk of instrument collision (36). Combining both surgical concepts may give surgeons the ability to achieve a relatively “scarless” operation with better surgical dynamics.

Following the introduction of SILS, single port systems subsequently led to the development of the transanal MIS technique, which is a derivative of natural orifice transluminal endoscopic surgery. Use of the TME concept via a transanal MIS approach (TaTME) has been associated with comparable surgical outcomes and better oncologic results for low and mid-rectal cancers especially (37-39). The COLOR III randomized trial (40) will provide a better perspective in terms of TaTME for the surgical community. The merits of using a robotic system led surgeons to adapt the robotic platform into TaTME in 2014 for the first time (41), and since then, the robotic TaTME approach has shown feasibility (42). Nonetheless, the bulky arms of da Vinci Xi platform are a drawback in endoluminal surgery. New systems with superior ergonomics in confined spaces have been recently approved including the Flex<sup>®</sup> Robotic System and Flex<sup>®</sup> Colorectal (CR) Drive (MedRobotics, Corp. Raynham, MA, USA).

Many solutions have been proposed to decrease rates of anastomotic leaks—one of the most dreadful complications in colorectal surgery where the underlying mechanism is thought to be insufficient tissue perfusion at the anastomosis site. Deciding where to place the anastomotic site mainly depends on active bleeding edge, mesenteric pulsatility and the color of the rectal segment. Lack of tactile feedback in MIS can make this difficult, although using a near-infrared camera on the robotic platform can allow surgeons to visualize the vascular structure of the colon following

indocyanine green injection and also help them identify the sentinel lymph node (43).

Although robotic platform offers ample opportunities for further innovations and constitutes a promising frontier in RCS, factors such as increased costs and prolonged operative time are still considered problems that prevent RRCS from being used more routinely. However, the as field of RCS continues to evolve and as the healthcare marketplace becomes more competitive, robotic surgery carries the potential to be the nexus for continued superior clinical outcomes.

### Acknowledgments

The tables in this manuscript are reproduced from the article published in *Journal of Surgical Oncology*. The authors would like to thank Amy Moore for her assistance during the review process of this manuscript.

*Funding:* None.

### Footnote

*Provenance and Peer Review:* This article was commissioned by the Guest Editors (Eduardo Ma Targarona and Andrea Balla) for the series “Rectal Cancer” published in *Annals of Laparoscopic and Endoscopic Surgery*. The article has undergone external peer review.

*Conflicts of Interest:* Both authors have completed the ICMJE uniform disclosure form (available at <http://dx.doi.org/10.21037/ales.2018.03.12>). The series “Rectal Cancer” was commissioned by the editorial office without any funding or sponsorship. The authors have no other conflicts of interest to declare.

*Ethical Statement:* The authors are accountable for all aspects of the work in ensuring that questions related to the accuracy or integrity of any part of the work are appropriately investigated and resolved.

*Open Access Statement:* This is an Open Access article distributed in accordance with the Creative Commons Attribution-NonCommercial-NoDerivs 4.0 International License (CC BY-NC-ND 4.0), which permits the non-commercial replication and distribution of the article with the strict proviso that no changes or edits are made and the original work is properly cited (including links to both the formal publication through the relevant DOI and the license).

See: <https://creativecommons.org/licenses/by-nc-nd/4.0/>.

## References

1. Stevenson AR, Solomon MJ, Lumley JW, et al. ALaCaRT Investigators. Effect of Laparoscopic-Assisted Resection vs Open Resection on Pathological Outcomes in Rectal Cancer: The ALaCaRT Randomized Clinical Trial. *JAMA* 2015;314:1356-63.
2. Fleshman J, Branda M, Sargent DJ, et al. Effect of Laparoscopic-Assisted Resection vs Open Resection of Stage II or III Rectal Cancer on Pathologic Outcomes: The ACOSOG Z6051 Randomized Clinical Trial. *JAMA* 2015;314:1346-55.
3. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery—the clue to pelvic recurrence? *Br J Surg* 1982;69:613-6.
4. Jayne D, Pigazzi A, Marshall H, et al. Effect of Robotic-Assisted vs Conventional Laparoscopic Surgery on Risk of Conversion to Open Laparotomy Among Patients Undergoing Resection for Rectal Cancer: The ROLARR Randomized Clinical Trial. *JAMA* 2017;318:1569-80.
5. Gorgun E, Ozben V, Costedio M, et al. Robotic versus conventional laparoscopic rectal cancer surgery in obese patients. *Colorectal Dis* 2016;18:1063-71.
6. Stulberg JJ, Delaney CP, Neuhauser DV, et al. Adherence to surgical care improvement project measures and the association with postoperative infections. *JAMA* 2010;303:2479-85.
7. Guillou PJ, Quirke P, Thorpe H, et al. MRC CLASICC trial group. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. *Lancet* 2005;365:1718-26.
8. Jayne DG, Guillou PJ, Thorpe H, et al. UK MRC CLASICC Trial Group. Randomized trial of laparoscopic-assisted resection of colorectal carcinoma: 3-year results of the UK MRC CLASICC Trial Group. *J Clin Oncol* 2007;25:3061-8.
9. Jeong SY, Park JW, Nam BH, et al. Open versus laparoscopic surgery for mid-rectal or low-rectal cancer after neoadjuvant chemoradiotherapy (COREAN trial): survival outcomes of an open-label, non-inferiority, randomised controlled trial. *Lancet Oncol* 2014;15:767-74.
10. van der Pas MH, Haglind E, Cuesta MA, et al. Colorectal cancer Laparoscopic or Open Resection II (COLOR II) Study Group. Laparoscopic versus open surgery for rectal cancer (COLOR II): short-term outcomes of a randomised, phase 3 trial. *Lancet Oncol* 2013;14:210-8.
11. Bonjer HJ, Deijen CL, Abis GA, et al. COLOR II Study Group. A randomized trial of laparoscopic versus open surgery for rectal cancer. *N Engl J Med* 2015;372:1324-32.
12. Barnajian M, Pettet D 3rd, Kazi E, et al. Quality of total mesorectal excision and depth of circumferential resection margin in rectal cancer: a matched comparison of the first 20 robotic cases. *Colorectal Dis* 2014;16:603-9.
13. Kim JC, Yu CS, Lim SB, et al. Comparative analysis focusing on surgical and early oncological outcomes of open, laparoscopy-assisted, and robot-assisted approaches in rectal cancer patients. *Int J Colorectal Dis* 2016;31:1179-87.
14. Cho MS, Baek SJ, Hur H, et al. Short and long-term outcomes of robotic versus laparoscopic total mesorectal excision for rectal cancer: a case-matched retrospective study. *Medicine (Baltimore)* 2015;94:e522.
15. Allemann P, Duvoisin C, Di Mare L, et al. Robotic-Assisted Surgery Improves the Quality of Total Mesorectal Excision for Rectal Cancer Compared to Laparoscopy: Results of a Case-Controlled Analysis. *World J Surg* 2016;40:1010-6.
16. Feroci F, Vannucchi A, Bianchi PP, et al. Total mesorectal excision for mid and low rectal cancer: Laparoscopic vs robotic surgery. *World J Gastroenterol* 2016;22:3602-10.
17. Ramji KM, Cleghorn MC, Josse JM, et al. Comparison of clinical and economic outcomes between robotic, laparoscopic, and open rectal cancer surgery: early experience at a tertiary care center. *Surg Endosc* 2016;30:1337-43.
18. Kang J, Yoon KJ, Min BS, et al. The impact of robotic surgery for mid and low rectal cancer: a case-matched analysis of a 3-arm comparison—open, laparoscopic, and robotic surgery. *Ann Surg* 2013;257:95-101.
19. Memon S, Heriot AG, Murphy DG, et al. Robotic versus laparoscopic proctectomy for rectal cancer: a meta-analysis. *Ann Surg Oncol* 2012;19:2095-101.
20. Cui Y, Li C, Xu Z, et al. Robot-assisted versus conventional laparoscopic operation in anus-preserving rectal cancer: a meta-analysis. *Ther Clin Risk Manag* 2017;13:1247-57.
21. Kim NK, Kang J. Optimal total mesorectal excision for rectal cancer: The role of robotic surgery from an expert's view. *J Korean Soc Coloproctol* 2010;26:377-87.
22. Baek JH, Pastor C, Pigazzi A. Robotic and laparoscopic total mesorectal excision for rectal cancer: A case-matched study. *Surg Endosc* 2011;25:521-5.
23. D'Annibale A, Pernazza G, Monsellato I, et al. Total

- mesorectal excision: A comparison of oncological and functional outcomes between robotic and laparoscopic surgery for rectal cancer. *Surg Endosc* 2013;27:1887-95.
24. Yoo BE, Cho JS, Shin JW, et al. Robotic versus laparoscopic intersphincteric resection for low rectal cancer: comparison of the operative, oncological, and functional outcomes. *Ann Surg Oncol* 2015;22:1219-25.
  25. Silva-Velazco J, Dietz DW, Stocchi L, et al. Considering Value in Rectal Cancer Surgery: An Analysis of Costs and Outcomes Based on the Open, Laparoscopic, and Robotic Approach for Proctectomy. *Ann Surg* 2017;265:960-8.
  26. Morelli L, Guadagni S, Lorenzoni V, et al. Robot-assisted versus laparoscopic rectal resection for cancer in a single surgeon's experience: a cost analysis covering the initial 50 robotic cases with the da Vinci Si. *Int J Colorectal Dis* 2016;31:1639-48.
  27. Jiménez-Rodríguez RM, Díaz-Pavón JM, de la Portilla de Juan F, et al. Learning curve for robotic-assisted laparoscopic rectal cancer surgery. *Int J Colorectal Dis* 2013;28:815-21.
  28. Sng KK, Hara M, Shin JW, et al. The multiphasic learning curve for robot-assisted rectal surgery. *Surg Endosc* 2013;27:3297-307.
  29. Yamaguchi T, Kinugasa Y, Shiomi A, et al. Learning curve for robotic-assisted surgery for rectal cancer: use of the cumulative sum method. *Surg Endosc* 2015;29:1679-85.
  30. Bege T, Lelong B, Esterni B, et al. The learning curve for the laparoscopic approach to conservative mesorectal excision for rectal cancer: lessons drawn from a single institution's experience. *Ann Surg* 2010;251:249-53.
  31. Kayano H, Okuda J, Tanaka K, et al. Evaluation of the learning curve in laparoscopic low anterior resection for rectal cancer. *Surg Endosc* 2011;25:2972-9.
  32. Ito M, Sugito M, Kobayashi A, et al. Influence of learning curve on short-term results after laparoscopic resection for rectal cancer. *Surg Endosc* 2009;23:403-8.
  33. Park EJ, Kim CW, Cho MS, et al. Is the learning curve of robotic low anterior resection shorter than laparoscopic low anterior resection for rectal cancer?: a comparative analysis of clinicopathologic outcomes between robotic and laparoscopic surgeries. *Medicine (Baltimore)* 2014;93:e109.
  34. Moghadamyeghaneh Z, Phelan M, Smith BR, et al. Outcomes of Open, Laparoscopic, and Robotic Abdominoperineal Resections in Patients with Rectal Cancer. *Dis Colon Rectum* 2015;58:1123-9.
  35. Holzmacher JL, Luka S, Aziz M, et al. The Use of Robotic and Laparoscopic Surgical Stapling Devices During Minimally Invasive Colon and Rectal Surgery: A Comparison. *J Laparoendosc Adv Surg Tech A* 2017;27:151-5.
  36. Kim SJ, Choi BJ, Lee SC. Overview of single-port laparoscopic surgery for colorectal cancers: past, present, and the future. *World J Gastroenterol* 2014;20:997-1004.
  37. Atallah S, Martin-Perez B, Albert M, et al. Transanal minimally invasive surgery for total mesorectal excision (TAMIS-TME): results and experience with the first 20 patients undergoing curative-intent rectal cancer surgery at a single institution. *Tech Coloproctol* 2014;18:473-80.
  38. Lacy AM, Tasende MM, Delgado S, et al. Transanal total mesorectal excision for rectal cancer: outcomes after 140 patients. *J Am Coll Surg* 2015;221:415-23.
  39. Tuech JJ, Karoui M, Lelong B, et al. A step toward NOTES total mesorectal excision for rectal cancer: endoscopic transanal proctectomy. *Ann Surg* 2015;261:228-33.
  40. Deijen CL, Velthuis S, Tsai A, et al. COLOR III: a multicentre randomised clinical trial comparing transanal TME versus laparoscopic TME for mid and low rectal cancer. *Surg Endosc* 2016;30:3210-5.
  41. Atallah S, Nassif G, Polavarapu H, et al. Robotic-assisted transanal surgery for total mesorectal excision (RATS-TME): a description of a novel surgical approach with video demonstration. *Tech Coloproctol* 2013;17:441-7.
  42. Atallah S, Martin-Perez B, Parra-Davila E, et al. Robotic transanal surgery for local excision of rectal neoplasia, transanal total mesorectal excision, and repair of complex fistulae: clinical experience with the first 18 cases at a single institution. *Tech Coloproctol* 2015;19:401-10.
  43. Buchs N. New trends in robotic colorectal surgery. *Adv Robot Autom* 2014;3:e117.

doi: 10.21037/ales.2018.03.12

**Cite this article as:** Cengiz TB, Gorgun E. Robotic approach for rectal cancer, is the best approach? *Ann Laparosc Endosc Surg* 2018;3:28.